Search the Newsreel

Incyte Grants Heeson Lee Stock Options and Performance Shares Worth Notable Equity Compensation

Incyte Corporation recently granted Heeson Lee, Executive Vice President and Head of Incyte International, significant equity compensation. This award, consisting of 15,423 employee stock options and 13,498 performance shares, was disclosed on July 27, 2026. This compensation aligns with the company's performance metrics and …

Form 4 Incyte Corporation For: 27 July By Investing.com

This article announces the filing of a Form 4 for Incyte Corporation (NASDAQ: INCY) on July 27. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings …

Incyte (NASDAQ: INCY) awards EVP stock options, 8,999 performance shares

Michael James Morrissey, EVP and Head of Technical Operations at Incyte, was granted 6,426 stock options with an exercise price of $116.69 and 8,999 performance shares on July 23, 2026. The stock options vest over approximately four years and expire in 2036, while the …

Incyte’s near-high close leaves confirmation burden on volume after a 21% quarter

INCY finished at $117.70, just 1.6% below its 52-week high, with an active Trend backdrop and positive Market Dynamics, but the latest move came on only 0.8x 13-week volume.

Incyte Corp (INCY) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Incyte Corp (INCY), listing its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings for key investors. Additionally, it lists various …

Incyte Corporation stock hits 52-week high at 119.6 USD

Incyte Corporation's stock reached a 52-week high of $119.60, reflecting a 68.7% increase over the past year and investor confidence in its performance. The company, with a market cap of $23.74 billion, boasts a P/E ratio of 16.68 and 21.48% revenue growth. Recent positive …

Incyte Corporation (INCY) Stock Analysis: Navigating a 20.9% Revenue Growth Surge in the Biotech Sector

INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings

INCYTE CORP (NASDAQ:INCY) is shown to have a strong technical breakout setup, marked by a perfect Technical Rating of 10 and a Setup Quality score of 9. This indicates a sustained uptrend and a consolidation pattern ideal for a potential breakout. The article suggests …

Incyte Corp. stock underperforms Monday when compared to competitors despite daily gains

Incyte Corp. (INCY) stock gained 1.02% on Monday, reaching $118.87, despite the broader market also seeing positive movement with the S&P 500 and Dow Jones Industrial Average rising. This marks the stock's third consecutive day of gains. However, this article indicates that its performance …

Incyte Q2 Earnings Preview: Can Commercial Growth Sustain A Catalyst-Rich Pipeline?

(RTTNews) - Incyte (INCY), a biopharmaceutical company, is scheduled to report second-quarter financial results on July 28, 2026. Incyte's key therapeutic areas of focus include Haematology, Oncology, Inflammation, and Autoimmunity. In addition to sales trends for Polycythemia vera drug Jakafi and Atopic dermatitis drug …

What To Expect From Incyte’s (INCY) Q2 Earnings

What To Expect From Incyte's (INCY) Q2 Earnings Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here's what to look for. Incyte beat analysts' revenue expectations last quarter, reporting revenues of $1.27 billion, up 20.9% year on year. …

Incyte (INCY) Reports Full Latarcibart Data And Buys Vega Therapeutics

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Incyte (NasdaqGS:INCY) reported full safety and efficacy results from its Phase 1/2 study of latarcibart, a once monthly subcutaneous therapy for von Willebrand …

INCY|Incyte Corp|Price:117.670|Chg%:+0.980

Incyte Corporation (INCY) is trading at $117.67, up 0.84%, with strong fundamental health and high growth potential. The company's valuation is considered fair within the Pharmaceuticals industry, and institutional ownership is high. Analysts generally rate it as a "Buy" with an average target price …

Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?

Incyte (INCY) is expected to report its second-quarter 2026 earnings on July 28, with analysts predicting a beat on both revenue and earnings. The company's performance is anticipated to be driven by strong sales of its lead drug, Jakafi, as well as Opzelura, and …

INCY Maintained by Morgan Stanley -- Price Target Raised to $104.00

Morgan Stanley has maintained its Equal-Weight rating for Incyte Corporation (INCY) and raised its price target to $104.00 from $103.00. Despite this slight increase, GuruFocus indicates that INCY is currently overvalued by 15.8% with a GF Value™ of $100.11 against a trading price of …

Incyte stock trades steadily as Jakafi revenue supports oncology pipeline

Incyte's stock performance is driven by strong Jakafi revenue, which anchors its commercial model, and the growing sales of its dermatology drug Opzelura, showcasing diversification. The company maintains a robust cash position and significant R&D investment for its oncology and immunology pipeline, balancing current …

Should Halozyme’s New ENHANZE–Incyte Oncology Pact Reshape How HALO Investors View Its Royalty Model?

Halozyme Therapeutics announced a new global collaboration with Incyte, leveraging its ENHANZE drug delivery technology for an oncology program. This partnership aims to broaden Halozyme's royalty streams in blood cancers, adding to its existing collaborations. While this new deal reinforces Halozyme's strategy of expanding …

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth

Incyte (INCY) is projected to announce an increase in earnings and revenue for the quarter ending June 2026, with an expected release date of July 28. The Zacks Consensus Estimate predicts earnings of $1.85 per share, up 17.8% year-over-year, and revenues of $1.4 billion, …

Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued

Halozyme Therapeutics recently partnered with Incyte, using its Enhanze technology for subcutaneous formulations. Despite a 12.46% share price increase over 30 days and long-term gains, the stock appears undervalued, with analysts estimating a fair value of $83.90 compared to its current $77.09. However, its …

Incyte Corp (INCY) awards RSUs, options and performance shares to CSO

Incyte Corporation's EVP & Chief Scientific Officer, Patrick A. Mayes, received significant equity awards on July 16, 2026. These awards include 5,916 restricted stock units vesting over four years, 25,538 stock options with an exercise price of $116.65, and 14,790 performance shares tied to …

Incyte Corp (INCY) grants RSUs and stock options to accounting chief

Incyte Corp's Principal Accounting Officer, Tray Thomas, received 2,834 restricted stock units (RSUs) and 4,079 employee stock options on July 16, 2026. The RSUs vest 25% annually over four years, while the stock options, with an exercise price of $116.65, vest initially 25% after …

Incyte Corp (INCY) CMO awarded RSUs, options and sells stock

Steven H. Stein, CMO & Head of Late-Stage Development at Incyte Corp (INCY), received various equity awards on July 16, 2026, including 9,798 RSUs, 42,298 stock options, and 24,496 performance shares. Concurrently, he sold 1,877 common shares at $114.73, leaving him with 21,118 directly …

Equity grants to INCYTE CORP (INCY) R&D head and holdings

INCYTE CORP's President, Global Head of R&D, Pablo J. Cagnoni, received equity compensation awards on July 16, 2026, including restricted stock units, employee stock options, and performance shares. These grants are part of his compensation package, with specific vesting schedules and performance criteria. Following …

Incyte Corp. stock underperforms Monday when compared to competitors

Incyte Corp. (INCY) stock fell 1.36% on Monday, closing at $115.65. This underperformance occurred during a generally poor trading session where the S&P 500 Index and Dow Jones Industrial Average also declined. The stock's dip ended a four-day winning streak.

Halozyme and Incyte announce global collaboration deal

Halozyme and Incyte have entered into a global collaboration and license agreement to develop subcutaneous drug formulations using Halozyme's ENHANZE technology. The partnership aims to advance treatments for mutCALR-expressing myeloproliferative neoplasms. Halozyme will receive an upfront payment, potential milestone payments, and royalties on net …

Halozyme ENHANZE Expands to Incyte's Myeloproliferative...

Halozyme Therapeutics has partnered with Incyte to integrate its ENHANZE drug delivery technology into Incyte's INCA033989, a first-in-class monoclonal antibody for myeloproliferative neoplasms that recently received FDA Breakthrough Therapy designation. The agreement grants Halozyme upfront payments, milestone payments, and royalties on net sales, and …

Halozyme partners with Incyte on drug delivery technology

Halozyme Therapeutics Inc. has announced a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE drug delivery technology. Halozyme will receive an upfront payment, eligibility for milestone payments and royalties, and Incyte can nominate additional targets. The …

Halozyme-Incyte Deal Aims for More Convenient INCA033989 Dosing

Halozyme has announced a global collaboration and license agreement with Incyte. The agreement focuses on developing subcutaneous formulations of INCA033989, a monoclonal antibody for myeloproliferative neoplasms, using Halozyme's ENHANZE® drug delivery technology. This partnership aims to enhance treatment convenience and dosing regimens for patients …

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Halozyme Therapeutics, Inc. (Nasdaq: HALO) has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE® drug delivery technology. This collaboration aims to improve the treatment experience for patients with mutCALR-expressing myeloproliferative neoplasms …

Incyte stock hits 52-week high at 118.98 USD By Investing.com

Incyte Corporation's stock reached a new 52-week high of $118.98, marking a 74.24% appreciation over the past year. The biopharmaceutical company boasts a market capitalization of $23.71 billion, a P/E ratio of 16.44, and an "EXCELLENT" financial health score according to InvestingPro data, despite …

Form 4 Incyte Corporation For: 16 July By Investing.com

The article reports on a Form 4 filing for Incyte Corporation (INCY) on July 16. It notes that the company's stock experienced a 1.36% increase. Beyond this brief mention, the article primarily consists of general financial market data, indices, commodity prices, and other unrelated …

Incyte Corp (NASDAQ: INCY) PAO reports 1,790 shares withheld for RSU taxes

Incyte Corp's Principal Accounting Officer, Tray Thomas, reported two tax-withholding dispositions of common stock totaling 1,790 shares on July 14-15, 2026, related to restricted stock unit settlements. After these transactions, Thomas directly holds 18,865 shares, including 10,236 shares from unvested RSUs. This activity is …

Incyte Corp (NASDAQ: INCY) EVP reports 1,949-share RSU tax withholding

Incyte Corp's EVP & Chief Scientific Officer, Patrick A Mayes, reported automatic tax-withholding dispositions for 1,949 shares of common stock on July 14-15, 2026. These transactions were executed to cover tax obligations related to restricted stock units (RSUs) and were not open-market sales. After …

Incyte (INCY) R&D chief withholds 22,919 shares to cover taxes

Incyte's President and Global Head of R&D, Pablo J. Cagnoni, reported withholding 22,919 shares of common stock to cover tax obligations arising from the settlement of restricted stock units and earned performance shares. These transactions, valued at $114.88 and $115.09 per share, were tax-related …

Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains

Incyte Corp. (INCY) shares gained 1.36% on Thursday, closing at $116.65, marking its third consecutive day of increases despite an overall negative trading session for the broader market. The S&P 500 and Dow Jones Industrial Average both experienced declines. However, Incyte's stock still underperformed …

What Do the Povorcitinib Trial Results Mean for Incyte

Incyte's Povorcitinib has shown strong long-term efficacy and a manageable safety profile in late-stage trials for moderate-to-severe Hidradenitis Suppurativa (HS), positioning it as a potential first-in-class oral treatment. The HS market represents a significant unmet need, offering a substantial new revenue stream for Incyte. …